Kodiak Sciences (KOD) Reports Q4 EPS of ($1.05)

Kodiak Sciences Inc. (NASDAQ:KOD) is one of the 8 Healthcare Stocks Insiders Are Buying. On April 1, 2026, Kodiak Sciences Inc. (NASDAQ:KOD) reported Q4 EPS of ($1.05) compared to (84c) last year. Victor Perlroth, M.D., Chief Executive Officer,  said momentum is building, citing “positive Phase 3 topline results” from the GLOW2 study and progress across late-stage and pipeline programs supporting the company’s long-term strategy.

On March 27, 2026, UBS raised its price target on Kodiak Sciences Inc. (NASDAQ:KOD) to $80 from $50 previously and maintained a Buy rating on the shares. UBS said it is bullish on both tarcocimab VEGF and IL6.

Kodiak Sciences (KOD) Reports Q4 EPS of ($1.05)

Photo by José Antonio Otegui Auzmendi on Pexels

Similarly, H.C. Jefferies raised its price target on Kodiak Sciences Inc. (NASDAQ:KOD) to $56 from $39 previously and maintained a Buy rating on the shares, noting GLOW2 results showed improved safety and efficacy versus GLOW1, with the reformulation seen as a safety improvement and potential driver of durability in the Phase III DAYBREAK study, while also supporting earlier Biologics License Application timing.

Kodiak Sciences Inc. (NASDAQ:KOD) develops therapies for retinal diseases.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.